SGLT2 inhibitors are more and more prescribed in the treatment of type 2 diabetes. Their cardioprotective and nephroprotective effects make them particularly attractive. However, it is important to be aware of their potential side effects. This article aims to summarize the actual evidence regarding the most studied ones. Euglycemic ketoacidosis, genital infections and hypovolemia have been well described. Evidence is less robust regarding the increased risk of amputations, fractures, urinary tract infection or acute kidney disease. This article also aims to summarize some key messages to discuss with patients, in order to prevent the occurrence of euglycemic ketoacidosis and hypovolemia.